Cardiovascular outcome in patients with dysglycemia with daily supplementation of n-3 fatty acids 1 ORIGIN trial (Outcome Reduction with an Initial Glargine INtervention) 1- The ORIGIN Trial Investigators. n-3 Fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012;367(4):

Patients screened for eligibility Patients included in run-in Patients randomized 6319 Received n-3 fatty acids 6292 Received placebo 1627 Excluded: 322 Did not meet inclusion criteria 10 Declined to participate 1295 Had other reasons 1154 Excluded: 356 Had ineligible plasma glucose 42 Were ineligible for other reasons 397 Were nonadherent in run-in 264 Withdrew consent 95 Had other reasons 6220 Had known outcome status 61 Did not have final outcome status 14 Withdrew consent 38 Did not give consent to extension 9 Were lost to follow-up 6208 Had known outcome status 47 Did not have final outcome status 18 Withdrew consent 20 Did not give consent to extension 9 Were lost to follow-up 6281 Were included in the analysis 6255 Were included in the analysis 38 Excluded by health authorities 37 Excluded by health authorities Median follow-up: 6.2 years

% Influence of the n-3 fatty acid regimen on mortality

% Influence of the n-3 fatty acid regimen on cardiovascular events

Conclusions Daily 1-g dose of n-3 fatty acids did not prevent death or any cardiovascular outcome in hyperglycemic or diabetic patients with high cardiovascular risk compared with placebo